Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Sep 15:380:250-255.
doi: 10.1016/j.jns.2017.07.048. Epub 2017 Aug 1.

Management of glioblastoma in elderly patients

Jacob S Young  1 , Steven J Chmura  2 , Derek A Wainwright  3 , Bakhtiar Yamini  4 , Katherine B Peters  5 , Rimas V Lukas  6
Affiliations
Review

Management of glioblastoma in elderly patients

Jacob S Young et al. J Neurol Sci. .

Abstract

Glioblastoma (GBM) is the most common primary malignant brain tumor in adults over 55years of age. The median age of diagnosis for patients with GBM is 64years old, with the incidence of patients between 75 and 85 increasing. The optimal treatment paradigm for elderly GBM patients continues to evolve due to the higher frequency of age-related and/or medical co-morbidities. Geriatric GBM patients have historically been excluded from larger, controlled clinical trials due to their presumed decreased likelihood of a sustained treatment response and/or a prolonged good outcome. Here, we highlight current treatment considerations of elderly GBM patients with respect to surgical, radiotherapeutic and systemic modalities, with considerations for improving future clinical outcomes for this patient population.

Keywords: Chemotherapy; Elderly; Geriatric; Glioblastoma; High-grade glioma; Radiation therapy; Surgical resection.

PubMed Disclaimer

Conflict of interest statement

Disclosures

R.V.L serves on advisory boards for Abbvie, Asta Zeneca, and Ziopharm, given an internal lecture/presentation for Abbvie, and received support for travel to a meeting from Roche. J.S.Y, S.J.C., D.A.W., B.Y., and K.B.P. have no disclosures.

References

    1. Bauchet L, Zouaoui S, Darlix A, Menjot de Champfleur N, Ferreira E, Fabbro M, et al., Assessment and treatment relevance in elderly glioblastoma patients, Neuro-Oncology 16 (2014) 1459–1468. - PMC - PubMed
    1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N. Engl. J. Med 352 (2005) 987–996. - PubMed
    1. Lukas RV, Mrugala MM, Pivotal therapeutic trials for infiltrating gliomas and how they affect clinical practice, Neuro-Oncol. Pract (2016) 10.1093/nop/npw016. - DOI - PMC - PubMed
    1. Buckner JC, Factors influencing survival in high-grade gliomas, Semin. Oncol 30 (2003) 10–14. - PubMed
    1. Kita D, Ciernik IF, Vaccarella S, Franceschi S, Kleihues P, Lutolf UM, et al., Age as a predictive factor in glioblastomas: population-based study, Neuroepidemiology 33 (2009) 17–22. - PubMed